82% Response Rate in Refractory Pancreatic Cancer; Phase 3 Set for 1H27
TNGX has more than doubled off its 52-week low of $6.69 on elevated volume (2.0× avg).
Summary
Tango reported an 82% overall response rate in 22 heavily pretreated (2L/3L) patients with MTAP-deleted/RAS-mutant pancreatic cancer on vopimetostat plus daraxonrasib. Median progression-free survival was not reached and the 9-month PFS rate was 88%, which points to durability rather than a transient response. The combination was generally well tolerated, supporting a move into front-line use. Tango plans a registrational Phase 3 trial in front-line MTAP-deleted PDAC to start in 1H 2027. This is the kind of data that shifts the thesis for a clinical-stage oncology name: a high response rate in a notoriously chemo-refractory tumor raises the probability of success and the commercial ceiling. The company ended Q2 with $1.0B in cash after a June raise and has a $400M at-the-market program in place, so funding the pivotal study is not the near-term constraint. The open question is whether the randomized Phase 3 confirms the single-arm signal against standard chemotherapy.
At the time of this announcement, TNGX was trading at $32.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7B. The 52-week trading range was $6.69 to $34.39. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.